Results of Operations and Financial Condition

Business Context and Reporting Period

This Form 8-K was filed by Damora Therapeutics, Inc. (formerly Galecto, Inc.) on March 6, 2026, with the earliest event reported on that date. The filing primarily announces a corporate name change and a corresponding change in the company's trading symbol on The Nasdaq Capital Market.

Key Financial Metrics

The filing provides limited financial data, focusing on liquidity as of February 28, 2026:

  • Cash and Cash Equivalents: Approximately $535 million (preliminary and unaudited).
  • Revenue, Profit, and Margins: The filing text does not provide a clear value for these metrics.
  • Debt: The filing text does not provide a clear value for debt obligations.

Material Changes

The primary material change reported is the rebranding of the company:

  • Name Change: The company changed its name from "Galecto, Inc." to "Damora Therapeutics, Inc." effective March 10, 2026.
  • Symbol Change: Trading on The Nasdaq Capital Market will commence under the new symbol "DMRA" starting March 10, 2026.
  • Stock Rights: There is no change to the Common Stock's CUSIP, par value, or voting rights.

Outlook, Risks, and Management Commentary

Management noted that the estimated cash balance of $535 million is preliminary and unaudited. The filing explicitly states that actual financial results may differ materially from these preliminary estimates. No specific forward-looking guidance regarding product development, clinical trials, or future revenue projections is included in this document. The filing includes standard disclaimers that the information under Item 2.02 and Item 7.01 is not deemed filed for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Verify the effective date of the name and symbol change (March 10, 2026) for trading purposes.
  • Confirm the updated ticker symbol "DMRA" on The Nasdaq Capital Market.
  • Review the company's next audited financial statement (10-K or 10-Q) to validate the preliminary $535 million cash position.
  • Check for any subsequent filings regarding the strategic rationale for the rebranding from Galecto to Damora Therapeutics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.